Ajulemic acid
Ajulemic acid (IP-751) is a synthetic cannabinoid derivative of the non-psychoactive THC metabolite 11-carboxy-THC which shows useful analgesic and anti-inflammatory effects without causing a subjective “high”.[1] It is being developed for the treatment of neuropathic pain and inflammatory conditions such as arthritis.[2] It does not however share the anti-emetic effects of other cannabinoids but may be useful for treating pain and chronic inflammatory conditions where nausea is not present.[3] Side effects include dry mouth, tiredness and dizziness. The mechanism of action has not yet been established, but ajulemic acid may activate the CB1 receptor in a different way to psychoactive cannabinoids. [4]
References
- ↑ Burstein SH, Karst M, Schneider U, Zurier RB. Ajulemic acid: A novel cannabinoid produces analgesia without a “high”. Life Sciences. 2004 Aug 6;75(12):1513-22.
- ↑ Mitchell VA, Aslan S, Safaei R, Vaughan CW. Effect of the cannabinoid ajulemic acid on rat models of neuropathic and inflammatory pain. Neuroscience Letters. 2005 Jul 15;382(3):231-5.
- ↑ Burstein S. Ajulemic acid (IP-751): synthesis, proof of principle, toxicity studies, and clinical trials. AAPS Journal. 2005 Jun 29;7(1):E143-8.
- ↑ Vann RE, Cook CD, Martin BR, Wiley JL. Cannabimimetic properties of ajulemic acid. Journal of Pharmacology and Experimental Therapeutics. 2007 Feb;320(2):678-86.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH